Starling Oncology (STLN): CEO bought ~$24K

~$24K

Approx. value · 23K sh @ $1.04

724K

Holds after · shares reported

Traded

Mar 26, 2025

Filed

Mar 28, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 26, 2025 · this disclosureInsiderCEO purchased ~$24K of TOI shares in the open market

What came next

1. Mar 26, 2025Insider · 7 peopleInsiders: 7 purchases (~$1.6M)
2. May 20, 2025Insider · 1 personInsiders: 2 sales (~$5.4M)
3. Jun 3, 2025Insider · 1 personInsiders: 2 sales (~$5.7M)
4. Jun 5, 2025Insider · 1 personInsiders: 2 sales (~$2.3M)

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Starling Oncology

For Starling Oncology, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its STLN page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Starling Oncology

• SEC Form 4Nov 10, 2026
• SEC Form 4Nov 10, 2026
• SEC Form 4Sep 5, 2025
• SEC Form 4Sep 5, 2025
• SEC Form 4Aug 21, 2025
• SEC Form 4Jun 9, 2025

Everything OQRO holds on this company is on its STLN page.